Our first half of 2024 report on longevity funding publishes at this time: the numbers, the offers and the outlook for the remainder of the yr.
The primary half of 2024 marked a pivotal second for longevity investments, showcasing a mixture of resilience and challenges. Based on our First Half Longevity Investment Report 2024, which Longevity.Expertise Editor-in-Chief Phil Newman unveiled at Longevity Traders Convention at this time, the sector attracted $4.69 billion USD throughout Q1 and Q2.
Whereas 2022 remains to be the yr to beat, with $9.45 billion secured, 2024 is already outperforming 2023 which solely managed $3.87 billion in financing – a stark reminder of the sector’s volatility. The present financing figures additionally spotlight the untapped potential in rising fields like longevity discovery platforms and neuropharma.
Key highlights
- Q1 2024 financing: $3.36 billion raised throughout 74 offers, with the US accounting for a whopping 92% of complete financing. Longevity discovery platforms led the area with $1.44 billion secured, pushed by investments in firms like Denali Therapeutics.
- Q2 2024 financing: Whereas the momentum slowed with $1.33 billion raised over 57 offers, neuropharma emerged as a dominant area, securing $760 million, because of key gamers like Intra-Mobile Therapies.
This funding sample underscores the rising curiosity in applied sciences that may prolong healthspan – years lived in good well being. Phil Newman, Editor-in-Chief of Longevity.Expertise, famous that the demographic shift in the direction of an growing old inhabitants is catalyzing an pressing want for modern well being options. “Strategic investments now may form not simply the way forward for healthcare however the high quality of life for billions,” he mentioned. Newman mentioned these points as as a part of his Investment metrics and trends in longevity presentation, in Gstaad.
Regardless of a notable decline from earlier years, the focus of funds in high-impact domains, resembling rejuvenation, mobile reprogramming and neuropharma, signifies that traders stay cautiously optimistic. The rise from $3.87 billion in 2023 to $4.69 billion within the first half of 2024 highlights progress regardless of the worldwide funding downturn, and likewise spotlights a deal with long-term progress areas like discovery platforms and genetic therapeutics.
Wanting forward
The First Half Longevity Investment Report 2024 reveals that, whereas monetary volatility stays, the sector continues to carry promise for these keen to navigate its complexities. As society confronts the realities of growing old, the surge in scientific developments – from mobile reprogramming to longevity medication – has by no means been extra crucial, and traders want to concentrate on the regulatory panorama and the complicated timelines concerned. The second half of the yr shall be watched carefully for additional alerts of restoration and growth within the longevity market.
This yr’s funding panorama demonstrates that the race for longevity breakthroughs is way from over, with strategic capital persevering with to again revolutionary remedies for age-related illnesses. Longevity science isn’t nearly residing longer – it’s adopting a data-driven preventive method centered on residing more healthy for longer.
Traders are inspired to maintain an in depth eye on rising domains, significantly in mobile reprogramming and neuropharma, as they’re poised to guide the following wave of breakthroughs within the longevity house.
Our report not solely analyses longevity offers by stage, area and site, it displays on related funding points such because the surge in reputation of semaglutides and the commensurate rise in counterfeit and illicit merchandise. Our report goals to information stakeholders in navigating the complexities of longevity funding, fostering sustainable progress in selling prolonged healthspans for everybody.
